Fyn and Src are Effectors of Oncogenic EGFR Signaling in Glioblastoma Patients

Activating EGFR mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived. We demonstrate that the Src family kinases (SFKs) Fyn and Src are effectors of oncogenic EGFR signaling, enhancing invasion and tumor cell survi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lu, Kan V., Zhu, Shaojun, Cvrljevic, Anna, Huang, Tiffany T., Sarkaria, Shawn, Ahkavan, David, Dang, Julie, Dinca, Eduard B., Plaisier, Seema B., Oderberg, Isaac, Lee, Yohan, Chen, Zugen, Caldwell, Jeremy S., Xie, Yongmin, Loo, Joseph A., Seligson, David, Chakravari, Arnab, Lee, Francis Y., Weinmann, Roberto, Cloughesy, Timothy F., Nelson, Stanley F., Bergers, Gabriele, Graeber, Thomas, Furnari, Frank B., James, C. David, Cavenee, Webster K., Johns, Terrance G., Mischel, Paul S.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2770839/
https://ncbi.nlm.nih.gov/pubmed/19690143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-0347
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars